Stock Information
Myriad Genetics Inc (MYGN)
Ticker Symbol: MYGN
Exchange: NASDAQ
Sector: Biotechnology
Market Cap: $429.72 mil
Piotroski score: 4
PE Ratio: N/A
EPS (TTM): -3.9529
Revenue (TTM): $8.82 M
Dividend Yield: N/A%
ROE: -79.81%
Latest News
-
Liquid Biopsy Products Market Report 2026-2031 Featuring Analysis of Roche, Illumina, Qiagen, MDxHealth, Novogen, BGI, Myriad Genetics and More
Fri, Mar 20, 2026 10:49 AM
-
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
Tue, Mar 17, 2026 8:05 PM
-
Myriad Genetics Gets FDA Approval Of MyChoice CDx Test As Companion Diagnostic For Zejula, PARP Inhibitor From GSK, For Patients With Advanced Ovarian Cancer
Tue, Mar 17, 2026 4:12 PM
-
2 High-Flying Stocks with Competitive Advantages and 1 We Brush Off
Tue, Mar 17, 2026 1:17 PM
Key Financials
Financial data not available
